Table 4– Factors associated with progression-free survival to chemotherapy
Progression-free survival monthsUnivariate analysis p-valueMultivariate analysis
HR95% CIp-value
Age
 <60 years5.9 (4.4–7.4)0.344
 >60 years6.0 (5.3–6.7)
Sex
 Female6.0 (4.9–7.1)0.428
 Male5.9 (4.9–7.0)
ECOG
 0–16.2 (4.8–7.5)0.0071.4871.064–2.0760.020
 2–45.2 (3.6–6.9)
Stage
 III8.7 (6.6–10.7)0.0011.5951.145–2.2220.006
 IV5.5 (4.9–6.1)
Smoking status
 Positive6.0 (5.1–6.8)0.808
 Negative5.9 (4.7–7.2)
Wood smoke exposure
 Positive27.6 (19.3–35.8)0.597
 Negative20.9 (13.4–28.3)
EGFR status
 Positive7.5 (6.2–8.8)0.297
 Negative5.5 (4.9–6.0)
Groups
 Intermediate5.5 (4.6–6.5)0.0090.8640.753–0.9920.039
 High6.4 (5.0–7.9)
  • Data are presented as median (95% CI), unless otherwise stated. HR: hazard ratio; ECOG: Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor.